Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.

Abstract excerpt

Sunitinib, a multi-targeted tyrosine kinase inhibitor, is frequently incorporated into the management of papillary thyroid carcinoma refractory to standard therapies. Although clinical trials are in progress, the mechanism of action in papillary thyroid carcinomas is not clear, especially regardi...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carcinoma, Papillary
• Share to Extracellular Signal-Regulated MAP Kinases
• Share to MAP Kinase Kinase Kinases